AZN Company Profile and Key Details
NASDAQ : AZN
AstraZeneca
$187.16
-0.29-0.16%
At Close 4:00 PM67.8
BESG ScoreESG Rating
Price Chart
Stock Price Today
AstraZeneca PLC (AZN) stock declined over -0.15%, trading at $187.16 on NYSE, down from the previous close of $187.45. The stock opened at $187.07, fluctuating between $186.59 and $190.67 in the recent session.
Stock Snapshot
187.45
Prev. Close
580.3B
Market Cap
186.59
Day Low
62.18
P/E Ratio
3.01
EPS (TTM)
2.1
Cash Flow per Share
187.07
Open
3.1B
Number of Shares
190.67
Day High
49.82%
Free Float in %
12.54
Book Value
3.19M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 05, 2026 | 187.07 | 190.67 | 186.58 | 187.16 | 3.38M |
| Feb 04, 2026 | 189.06 | 190.70 | 186.32 | 187.45 | 3.89M |
| Feb 03, 2026 | 187.61 | 190.72 | 183.63 | 184.32 | 2.66M |
| Feb 02, 2026 | 93.03 | 192.79 | 93.03 | 188.41 | 3.16M |
| Jan 30, 2026 | 93.03 | 93.51 | 92.46 | 92.77 | 5.55M |
| Jan 29, 2026 | 93.37 | 93.53 | 92.57 | 92.59 | 6.44M |
| Jan 28, 2026 | 93.17 | 93.84 | 92.90 | 93.22 | 7.96M |
| Jan 27, 2026 | 94.65 | 96.18 | 94.65 | 95.60 | 6.55M |
| Jan 26, 2026 | 93.14 | 94.59 | 93.08 | 94.23 | 5.6M |
| Jan 23, 2026 | 92.06 | 92.99 | 91.44 | 92.95 | 4.31M |
| Jan 22, 2026 | 90.45 | 91.79 | 90.17 | 91.69 | 6.12M |
| Jan 21, 2026 | 89.68 | 90.79 | 89.04 | 90.54 | 9.1M |
| Jan 20, 2026 | 90.14 | 91.12 | 89.17 | 89.94 | 10.99M |
| Jan 16, 2026 | 94.47 | 94.68 | 93.51 | 94.39 | 54.7M |
| Jan 15, 2026 | 95.30 | 95.36 | 93.41 | 93.99 | 9.08M |
| Jan 14, 2026 | 96.02 | 96.43 | 95.37 | 96.34 | 7.71M |
| Jan 13, 2026 | 94.14 | 94.54 | 92.78 | 94.51 | 8.03M |
| Jan 12, 2026 | 95.14 | 95.18 | 93.41 | 93.63 | 10.53M |
| Jan 09, 2026 | 95.24 | 95.94 | 94.54 | 94.65 | 6.07M |
| Jan 08, 2026 | 95.18 | 95.95 | 93.22 | 94.01 | 5.58M |
Contact Details
About Company
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Company Information
| Employees | 94300 |
| Beta | 0.19 |
| Sales or Revenue | $45.81B |
| 5Y Sales Change% | 0.681% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Stock Peers
AMGN
1.6+0.44%
Amgen Inc.$367.80BIIB-0.09-0.05%
Biogen Inc.$185.36GILD3.14+2.15%
Gilead Sciences, Inc.$149.37HZNP00
Horizon Therapeutics Public Limited Company$116.30SNY-0.59-1.23%
Sanofi$47.49GRFS-0.35-3.67%
Grifols, S.A.$9.19SCLX-0.89-10.17%
Scilex Holding Company$7.86MIRA-0.08-6.61%
MIRA Pharmaceuticals, Inc.$1.13CTOR-0.04-3.48%
Citius Oncology, Inc.$1.11SCLXW-0.0119-7.83%
Scilex Holding Company$0.14Company Overview
AstraZeneca PLC (NYSE:AZN) closed at $187.16 USD, losing -$0.29 (-0.15%) from the previous close of $187.45. The stock is currently within 5% of its 52-week high $93.03 and $195.00. With a market capitalization of about $580.30 billion, AstraZeneca PLC is classified as a mega-cap and shows lower-than-market volatility (beta ~0.19). Key stats such as the average daily volume over the past year has been around 163.47 thousand shares, trading with heavier-than-usual volume. Headquartered in Cambridge, None, AstraZeneca PLC operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Pascal Claude Roland Soriot, the company employs approximately 94,300 people and listed since May 12, 1993. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Technical Performance
Short-term trend indicators are bearishly aligned (SMA20 0.85%, SMA50 1.92%, SMA200 18.01%). The stock’s 14-day RSI is 52.94 (neutral), while the ATR of 6.64 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -4.02% below its high and over 53.08% above its low. Average 10-day trading volume of 4.95 million shares is below the 3-month average of 6.30 million, indicating normal recent market interest.
Valuation Metrics
AstraZeneca PLC trades at a P/E ratio of 62.45, slightly above the S&P 500 average, with a price-to-sales ratio of 10.01 and a price-to-book ratio of 12.79 reflecting a rich premium to book value. The P/FCF stands at 52.2, also above market averages. Compared to sector medians, AstraZeneca PLC P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.
Dividend & Fair Value
AstraZeneca PLC last paid a dividend of 1.56 per share, this equals a trailing yield of roughly 3.72%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $168.64. This means the shares are trading above this model’s fair value.
Earnings & Analyst Outlook
AstraZeneca PLC generated EPS of $6.02 over the past year. Five-year average earnings growth is 34.63%. The latest quarter delivered EPS of $1.19. The next quarter is forecast at $nan. Next year's EPS is expected at $14.05. AstraZeneca PLC earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 06, 2025, missed forecasts by 4.39%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 3.13% in July 25, 2024.
Shareholding & Insider Activity
AstraZeneca PLC has 3.10 billion shares outstanding. The public float is 1.54 billion shares, elevated short interest at 0.35% of float. This equals 10.94 million shares. The short ratio is 2.18 days. Institutional investors hold 16.73% of the float. Insiders own 0.0%.
Financial & Profitability Overview
On valuation metrics, AstraZeneca trades at a P/E of 62.45, P/S of 10.01 and P/B of 12.79. Liquidity is tight, with a current ratio of 0.88 and quick ratio of 0.69. Operationally, the company’s inventory turnover is 1.56 and cash conversion cycle is -563.18 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.71, supported by a cash flow-to-debt ratio of 0.46.
Quarterly Financial Highlights
The company ended the quarter with $5.86B in cash and short-term investments, a total debt of $28.62B, and net debt of $22.78B. Total assets were $101.12B, with equity of $39.17B. Financials further reflected stability, with operating cash flow of $10.35B, free cash flow of $6.57B, and capital expenditures of - $3.78B.
Frequently Asked Questions
What is the current AstraZeneca PLC (AZN) stock price?
AstraZeneca PLC (NASDAQ: AZN) stock price is $187.16 in the last trading session. During the trading session, AZN stock reached the peak price of $190.67 while $186.59 was the lowest point it dropped to. The percentage change in AZN stock occurred in the recent session was -0.15% while the dollar amount for the price change in AZN stock was - $0.29.
AZN's industry and sector of operation?
The NASDAQ listed AZN is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. AstraZeneca PLC designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of AZN?
No Data
How AZN did perform over past 52-week?
AZN's closing price is 101.18% higher than its 52-week low of $93.03 where as its distance from 52-week high of $195.00 is -4.02%.
How many employees does AZN have?
Number of AZN employees currently stands at 94,300.
Link for AZN official website?
Official Website of AZN is: https://www.astrazeneca.com
How do I contact AZN?
AZN could be contacted at phone 442 037 495000 and can also be accessed through its website. AZN operates from 1 Francis Crick Avenue, Cambridge, CB2 0AA, United Kingdom.
How many shares of AZN are traded daily?
AZN stock volume for the day was 3.19M shares. The average number of AZN shares traded daily for last 3 months was 163.47K.
What is the market cap of AZN currently?
The market value of AZN currently stands at $580.30B with its latest stock price at $187.16 and 3.1B of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep